PCSK9 inhibitors for acute coronary syndrome: the era of early implementation

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new cholesterol-lowering strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting PCSK9 and reducing the degradation of LDL receptors; thus, they are impacting the management of dyslipidemia to the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hongzhen, Chen, Xiaomin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185746/
https://www.ncbi.nlm.nih.gov/pubmed/37200976
http://dx.doi.org/10.3389/fcvm.2023.1138787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185746/
https://www.ncbi.nlm.nih.gov/pubmed/37200976
http://dx.doi.org/10.3389/fcvm.2023.1138787

Ejemplares similares